期刊文献+

中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊疗指南 被引量:32

原文传递
导出
摘要 原发性肺癌(简称肺癌)是我国最常见的恶性肿瘤之一。根据世界卫生组织(WHO)癌症Globocan数据库,2012年我国新发肺癌患者达65.28万,居所有恶性肿瘤之首,约占全球1/3,
出处 《中华病理学杂志》 CAS CSCD 北大核心 2015年第10期696-703,共8页 Chinese Journal of Pathology
  • 相关文献

参考文献41

  • 1WHO. Globoean 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 [EB/OL]. [2015437-06]. http :// globocan, iarc. fr/Pages/online, aspx.
  • 2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448(7153):561-566.
  • 3Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS [J]. Cancer, 2009, 115(8) :1723-1733.
  • 4Shackelford RE, Vora M, Mayhall K, et al. ALK-rearrangements and testing methods in non-small cell lung cancer : a review [J]. Genes Cancer, 2014, 5(1-2):1-14.
  • 5Vidal J, Clav S, de Muga S, et al. Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients[J]. J Thorac Oneol, 2014, 9(12):1816-1820.
  • 6Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features[J]. Lung Cancer, 2014, 84 (2) : 121-126.
  • 7Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 370 ( 13 ) : 1189-1197.
  • 8Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [J]. N Engl J Med, 2014, 371 (23) :2167-2177.
  • 9Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013, 368(25):2385-2394.
  • 10Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROSl-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 371 (21) : 1963-1971.

二级参考文献32

  • 1Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature,2007,448(7153):561-566.
  • 2Wong DW,Leung EL,So KK,et al.The EML4 ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer,2009,115(8):1723-1733.
  • 3Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol,2009,27(26):4247-4253.
  • 4Shaw AT.Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced,ALK-positive NSCLC (PROFILE 1007).35th ESMO,2012,abstract LBA1.
  • 5全国肿瘤防治研究办公室/全国肿瘤登记中心/卫生部疾病预防控制局.2009全国肿瘤登记年报.北京:军事医学科学出版社.2010.
  • 6Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell,2007,131 (6):1190-1203.
  • 7Mitsudomi T,Suda K,Tomizawa K,et al.Clinico-pathologic features of lung cancer with EML4-ALK translocation.J Clin Oncol,2010 (suppl):abstr 10598.
  • 8Zhang X,Zhang S,Yang X,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer,2010,9:188.
  • 9Wu SG,Kuo YW,Chang YL,et al.EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR.J Thorac Oucol,2012,7(1):98-104.
  • 10Rodig SJ,Mino-Kenudson M,Dacic S,et al.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res,2009,15(16):5216-5223.

共引文献107

同被引文献211

引证文献32

二级引证文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部